help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rendell, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rendell, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Diabetes

Journal of Clinical Endocrinology & Metabolism, Vol 57, 1198-1206, Copyright © 1983 by Endocrine Society


ARTICLES

C-peptide levels as a criterion in treatment of maturity-onset diabetes

M Rendell

C-Peptide levels, both basal and glucose-stimulated, were contrasted in diet-controllable vs. nondiet-controllable maturity-onset diabetic patients. Fasting and glucose-stimulated plasma C-peptide values in diet-controlled diabetics were similar to those in normal subjects. Diabetic patients who were not solely diet controllable could be differentiated into two subgroups. One diet failure subgroup was truly insulin dependent, in that insulin treatment could not be stopped for even a brief period. In these patients, fasting C-peptide levels were very low, in the same range as in the majority of juvenile-onset diabetic patients. In the second diet failure subgroup, it was possible to manage patients without insulin therapy for varying periods of time, although most patients eventually needed insulin. Fasting C-peptide levels in this second subgroup were also in the same range as those in normal subjects. However, their C-peptide responses to glucose were significantly blunted. Measurement of C-peptide may furnish a useful criterion for the categorization of maturity-onset diabetic patients. Furthermore, C-peptide levels help considerably in the selection of treatment modalities for these patients. Low C-peptide levels identify those patients who require insulin treatment, whereas high C-peptide levels in insulin-treated patients suggest the possibility of discontinuing insulin.


This article has been cited by other articles:


Home page
NEJMHome page
M. Rendell
Dietary Treatment of Diabetes Mellitus
N. Engl. J. Med., May 11, 2000; 342(19): 1440 - 1441.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1983 by The Endocrine Society